LYEL compared with BOLD: revenue, margins and what each company keeps, and the suppliers and customers both name

LYELLyell Immunopharma, Inc.

Mkt capRevenueRevenue

BOLDBoundless Bio, Inc.

Mkt capRevenueRevenue

Compare

LYELLyell Immunopharma, Inc.

BOLDBoundless Bio, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LYEL1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±35.4%▲+3.52%×0.10

BOLD

No earnings history for BOLD.

= impliedLYEL realized, solidBOLD realized, hatchedOne scale, both sides: full bar = 36%× = |realized| ÷ impliedSource: market data

LYELLyell Immunopharma, Inc.

10.96▼−3.03%· post 10.96

Mkt cap$270.5MRevenue$4,000Q2 FY26Revenue$36,000FY25

BOLDBoundless Bio, Inc.

2.45▼−1.21%· post 2.45

ClosedOct 30 '26

Mkt cap$56.2MRevenue—Revenue—

Compare

ClosedOct 30 '26

LYELLyell Immunopharma, Inc.

BOLDBoundless Bio, Inc.

10.96▼−3.03%post 10.96

Price

2.45▼−1.21%post 2.45

$270.5M

Mkt cap

$56.2M

Q2 FY26$4,000

Revenue

—

FY25$36,000

Revenue

—

LYEL10.96▼−3.03%vsBOLD2.45▼−1.21%ClosedOct 30 '26